New UPLC-MS/MS bioanalytical method for quantification of Glycopyrronium and Indacaterol

We are glad to announce that a new method has been successfully developed and validated for determination of Glycopyrronium and Indacaterol in human plasma by LC/MS/MS with a calibration range of 1-200 pg/mL and 2-250 pg/mL, respectively.

Since both analytes can be quantified in a single run, it allows for reduced volumes of blood required, a faster turnaround time for sample analysis and significant cost advantages.
The method involves a solid-phase extraction procedure. Glycopyrronium, Indacaterol and internal standards are measured by reversed phase ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS).

The development of this assay adds to the long experience of Anapharm with high sensitivity methods for inhaled drugs including Tiotropium, Fluticasone, Salmeterol and Formoterol.


07/04/2022 10:15

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2024.

23/03/2022 15:12

Anapharm Bioanalytics acquires a new high sensitivity equipment: SCIEX Triple Quad 6500+ system

Anapharm Bioanalytics’ small molecule division continues to expand its capabilities with the acquisition of a new LC-MS/MS equipment tailored for method development and validation of high sensitivity assays

02/12/2021 14:33

Challenges in the Detection of Metabolic Biomarkers Using a Multi Plex Assay

A 5 Plex method for the detection of metabolic biomarkers in human plasma was developed using the U-PLEX technology on the MSD platform.

The complexities surrounding this method were the establishment of endogenous QCs for each chosen biomarker and evaluating the potential use and need for buffer QCs vs matrix QCs where applicable. Additional challenges were faced while trying to ascertain a single minimum required dilution to enable accurate quantification of all biomarkers simultaneously, encompassing the different detection ranges and limits for each biomarker.